YouthBio Therapeutics is at the forefront of developing tissue-specific gene therapies aimed at rejuvenating tissues, enhancing organ function, and potentially delaying the aging process. The company focuses on harnessing cellular reprogramming techniques, particularly utilizing Yamanaka factors, to restore youthful gene expression profiles in targeted cells. This innovative approach aims to address age-related diseases, starting with single-organ therapies, such as those for brain diseases like Alzheimer's. By employing a two-step gene therapy that emphasizes tissue specificity, YouthBio seeks to optimize the therapeutic effects of partial reprogramming, which has shown promise in various studies for improving muscle and heart regeneration, as well as rejuvenating intervertebral discs.

The scientific foundation of YouthBio's work is built on the premise that aging is epigenetically controlled and potentially reversible. Their research indicates that by delivering genes responsible for epigenetic rejuvenation into specific tissues, they can roll back the epigenetic clock, effectively rejuvenating those tissues. Importantly, the therapies are designed to avoid certain organs, such as the liver and intestine, to enhance safety and efficacy. Numerous studies have demonstrated the potential of partial reprogramming to reverse aging hallmarks at both cellular and organismal levels, providing a robust basis for YouthBio's mission to develop therapies that could significantly improve healthspan and lifespan.

Canada

Developing partial reprogramming gene therapies

Age-related diseases

YouthBio Therapeutics

Company Details